Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Receivables (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Receivables for 12 consecutive years, with $831000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 5.78% year-over-year to $831000.0, compared with a TTM value of $831000.0 through Sep 2025, down 5.78%, and an annual FY2024 reading of $1.2 million, up 132.21% over the prior year.
  • Receivables was $831000.0 for Q3 2025 at Arcadia Biosciences, down from $1.3 million in the prior quarter.
  • Across five years, Receivables topped out at $3.9 million in Q2 2022 and bottomed at $304000.0 in Q3 2023.
  • Average Receivables over 5 years is $1.3 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Receivables surged 289.54% in 2021, then plummeted 88.85% in 2023.
  • Year by year, Receivables stood at $1.4 million in 2021, then decreased by 12.41% to $1.2 million in 2022, then plummeted by 57.83% to $506000.0 in 2023, then surged by 132.21% to $1.2 million in 2024, then decreased by 29.28% to $831000.0 in 2025.
  • Business Quant data shows Receivables for RKDA at $831000.0 in Q3 2025, $1.3 million in Q2 2025, and $1.6 million in Q1 2025.